AORT Artivion
- 27.880
- -0.200-0.71%
- 27.880
- 0.0000.00%
Artivion News
JMP Securities Maintains Artivion(AORT.US) With Buy Rating, Maintains Target Price $33
Artivion Analyst Ratings
Needham Maintains Artivion(AORT.US) With Buy Rating, Maintains Target Price $34
Analysts' Opinions Are Mixed on These Healthcare Stocks: Artivion (AORT) and Revance Therapeutics (RVNC)
Lake Street Maintains Artivion(AORT.US) With Buy Rating, Maintains Target Price $35
Lake Street Reaffirms Their Buy Rating on Artivion (AORT)
A Quick Look at Today's Ratings for Artivion(AORT.US), With a Forecast Between $32 to $35
Artivion Is Maintained at Outperform by Oppenheimer
Artivion Analyst Ratings
Artivion (AORT) Gets a Buy From Oppenheimer
Needham Maintains Artivion(AORT.US) With Buy Rating, Raises Target Price to $34
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Artivion (AORT) and RxSight (RXST)
JMP Securities Maintains Artivion(AORT.US) With Buy Rating, Maintains Target Price $33
Artivion's Strong Financial Performance and Strategic Growth Opportunities Drive Buy Rating
Lake Street Maintains Artivion(AORT.US) With Buy Rating, Maintains Target Price $32
Lake Street Maintains Artivion(AORT.US) With Buy Rating, Maintains Target Price $32
Lake Street Maintains Artivion(AORT.US) With Buy Rating, Maintains Target Price $32
Lake Street Maintains Artivion(AORT.US) With Buy Rating, Maintains Target Price $32
Artivion Initiated at Market Outperform by JMP Securities
Artivion Analyst Ratings
No Data